RI
RTW INVESTMENTS, LP
RTW INVESTMENTS, LP · Investor
1Y performance ⓘ
+55%
AUM (13F)
$9.9B
# of Holdings
87
3Y performance ⓘ
+30%
vs S&P 500 ⓘ
−42%
Updated
Mar 31
RTW INVESTMENTS, LP's RTW INVESTMENTS, LP holds 87 U.S.-equity positions worth $9.9B (SEC 13F, Q1 2026). Top positions: Madrigal Pharmaceuticals, Inc. Common Stock 10.4%, Insmed, Inc. 7.9%, Protagonist Therapeutics, Inc 5.3%. 13F-replication return is +30% over 3 years (-42 pts vs the S&P 500) — a replicated, non-audited figure.
Holdings
| Stock | % of portfolio | Shares | Value | Latest activity | Avg buy price | Current price | Date |
|---|---|---|---|---|---|---|---|
| MDGL Madrigal Pharmaceuticals, Inc. Common Stock | 10.4% | 2.0M | $1.0B | — | $231.00 | $512.88 (+122%) | 2026-03-31 |
| INSM Insmed, Inc. | 7.9% | 4.8M | $792M | — | $21.10 | $98.61 (+367%) | 2026-03-31 |
| PTGX Protagonist Therapeutics, Inc | 5.3% | 5.1M | $533M | — | $23.00 | $115.03 (+400%) | 2026-03-31 |
| PTCT PTC Therapeutics, Inc. | 5.2% | 7.7M | $528M | — | $48.44 | $80.96 (+67%) | 2026-03-31 |
| ARGX Argenx Se | 5.2% | 709K | $518M | ▲ 5.3% (+36K) | $372.58 | $903.75 (+143%) | 2026-03-31 |
| CGON CG Oncology, Inc. Common stock | 4.7% | 7.0M | $473M | ▲ 247% (+5.0M) | $43.90 | $66.25 (+51%) | 2026-03-31 |
| CELC Celcuity Inc. Common Stock | 3.5% | 3.0M | $347M | ▲ 452% (+2.5M) | $99.74 | $89.93 (−10%) | 2026-03-31 |
| TNGX Tango Therapeutics, Inc. | 2.8% | 13.3M | $278M | ▲ 792% (+11.8M) | $9.90 | $28.50 (+188%) | 2026-03-31 |
| ERAS Erasca, Inc. Common Stock | 2.6% | 16.2M | $261M | ▲ 10917% (+16.0M) | $3.72 | $15.08 (+305%) | 2026-03-31 |
| NTRA Natera, Inc. Common Stock | 2.5% | 1.2M | $250M | ▼ 17% (−250K) | $55.52 | $228.80 (+312%) | 2026-03-31 |
| RDNT RadNet, Inc. Common Stock | 2.4% | 4.3M | $239M | ▲ 8.8% (+346K) | $34.77 | $55.76 (+60%) | 2026-03-31 |
| TARS Tarsus Pharmaceuticals, Inc. Common Stock | 2.3% | 3.3M | $235M | — | $12.57 | $63.56 (+406%) | 2026-03-31 |
| APGE Apogee Therapeutics, Inc. Common Stock | 2.3% | 2.8M | $234M | ▲ 2.6% (+70K) | $21.30 | $132.55 (+522%) | 2026-03-31 |
| SYRE Spyre Therapeutics, Inc. Common Stock | 2.1% | 4.2M | $210M | — | $21.52 | $100.32 (+366%) | 2026-03-31 |
| COGT Cogent Biosciences, Inc. Common Stock | 2.1% | 5.5M | $210M | ▼ 28% (−2.1M) | $14.36 | $35.84 (+150%) | 2026-03-31 |
| IRTC iRhythm Holdings, Inc. Common Stock | 2.0% | 1.7M | $197M | ▲ 41% (+487K) | $177.44 | $104.69 (−41%) | 2026-03-31 |
| STOK Stoke Therapeutics, Inc. Common Stock | 1.8% | 5.6M | $183M | ▲ 1.4% (+77K) | $8.33 | $30.97 (+272%) | 2026-03-31 |
| CYTK Cytokinetics Inc. | 1.8% | 2.7M | $179M | — | $35.19 | $79.17 (+125%) | 2026-03-31 |
| ACAD Acadia Pharmaceuticals Inc. | 1.6% | 7.1M | $159M | — | $18.82 | $22.09 (+17%) | 2026-03-31 |
| ESTA Establishment Labs Holdings Inc. | 1.5% | 2.7M | $151M | ▲ 2.6% (+67K) | $67.74 | $86.06 (+27%) | 2026-03-31 |
| IMCR Immunocore Hldgs Plc | 1.5% | 4.9M | $147M | — | $49.44 | $29.35 (−41%) | 2026-03-31 |
| RGEN Repligen Corp | 1.4% | 1.2M | $142M | ▲ 13% (+142K) | $163.86 | $126.57 (−23%) | 2026-03-31 |
| NBIX Neurocrine Biosciences Inc | 1.4% | 1.1M | $140M | — | $125.69 | $161.62 (+29%) | 2026-03-31 |
| GH Guardant Health, Inc. Common Stock | 1.4% | 1.5M | $137M | — | $23.44 | $128.83 (+450%) | 2026-03-31 |
| IMTX Immatics N.V. Ordinary Shares | 1.3% | 12.9M | $127M | ▲ 13% (+1.4M) | $6.90 | $9.78 (+42%) | 2026-03-31 |
| ZLAB Zai Lab Ltd | 1.2% | 6.6M | $124M | ▼ 5.5% (−385K) | $26.19 | $18.48 (−29%) | 2026-03-31 |
| BLTE Belite Bio Inc | 1.1% | 715K | $114M | — | $74.00 | $147.07 (+99%) | 2026-03-31 |
| ISRG Intuitive Surgical Inc. | 1.0% | 220K | $101M | ▲ 117% (+119K) | $341.94 | $402.95 (+18%) | 2026-03-31 |
| ORKA Oruka Therapeutics, Inc. Common Stock | 1.0% | 2.1M | $101M | — | $24.51 | $85.38 (+248%) | 2026-03-31 |
| GHRS GH Research PLC Ordinary Shares | 0.8% | 5.9M | $83M | — | $7.99 | $22.09 (+176%) | 2026-03-31 |
| XNCR Xencor, Inc. | 0.8% | 6.8M | $82M | — | $20.11 | $14.01 (−30%) | 2026-03-31 |
| URGN UroGen Pharma Ltd. Ordinary Shares | 0.8% | 4.5M | $82M | — | $9.24 | $34.99 (+279%) | 2026-03-31 |
| CNTA Centessa Pharmaceuticals Plc | 0.8% | 2.1M | $82M | ▲ 15% (+263K) | $15.99 | $40.18 (+151%) | 2026-03-31 |
| IMVT Immunovant, Inc. Common Stock | 0.8% | 3.2M | $79M | — | $24.77 | $38.10 (+54%) | 2026-03-31 |
| RARE Ultragenyx Pharmaceutical Inc. | 0.8% | 3.6M | $76M | ▲ 22% (+649K) | $40.10 | $29.03 (−28%) | 2026-03-31 |
| HNGE Hinge Health, Inc. | 0.7% | 1.9M | $74M | ▲ 446% (+1.6M) | $46.45 | $68.85 (+48%) | 2026-03-31 |
| CSTL Castle Biosciences, Inc. Common Stock | 0.7% | 2.8M | $68M | ▲ 30% (+643K) | $22.72 | $21.20 (−7%) | 2026-03-31 |
| RCKT Rocket Pharmaceuticals, Inc. Common Stock | 0.6% | 17.7M | $63M | — | $17.13 | $3.46 (−80%) | 2026-03-31 |
| TSHA Taysha Gene Therapies, Inc. Common Stock | 0.6% | 13.7M | $61M | ▼ 17% (−2.7M) | $3.16 | $6.53 (+107%) | 2026-03-31 |
| ALKS Alkermes Inc. plc | 0.6% | 1.7M | $59M | — | $28.01 | $46.02 (+64%) | 2026-03-31 |
| CMPS Compass Pathways Plc | 0.6% | 10.6M | $59M | ▲ 21% (+1.9M) | $3.78 | $12.63 (+234%) | 2026-03-31 |
| KOD Kodiak Sciences Inc Common Stock | 0.6% | 1.5M | $57M | — | $27.96 | $36.63 (+31%) | 2026-03-31 |
| REPL Replimune Group, Inc. | 0.6% | 7.4M | $56M | ▲ 3.0% (+217K) | $9.00 | $11.18 (+24%) | 2026-03-31 |
| CRNX Crinetics Pharmaceuticals, Inc. | 0.5% | 1.5M | $53M | ▲ 7.4% (+100K) | $28.76 | $35.38 (+23%) | 2026-03-31 |
| QURE uniQure N.V. | 0.4% | 2.6M | $42M | ▼ 30% (−1.1M) | $4.93 | $44.39 (+800%) | 2026-03-31 |
| WAY Waystar Holding Corp. Common Stock | 0.4% | 1.6M | $39M | NEW (+1.6M) | $24.11 | $17.31 (−28%) | 2026-03-31 |
| ARWR Arrowhead Research Corporation | 0.4% | 586K | $37M | — | $66.39 | $82.00 (+24%) | 2026-03-31 |
| OBIO Orchestra BioMed Holdings, Inc. Ordinary Shares | 0.3% | 8.3M | $35M | — | $19.57 | $4.08 (−79%) | 2026-03-31 |
| VSTM Verastem, Inc. | 0.3% | 6.6M | $35M | — | $6.03 | $4.25 (−30%) | 2026-03-31 |
| EVMN Evommune, Inc. | 0.3% | 1.5M | $35M | ▲ 17% (+219K) | $17.12 | $22.55 (+32%) | 2026-03-31 |
Showing top 50 of 87 holdings by value.
FAQ ▾
What are RTW INVESTMENTS, LP's largest holdings?
As of the latest 13F: Madrigal Pharmaceuticals, Inc. Common Stock 10.4%, Insmed, Inc. 7.9%, Protagonist Therapeutics, Inc 5.3%, PTC Therapeutics, Inc. 5.2%, Argenx Se 5.2%.
How big is RTW INVESTMENTS, LP's 13F portfolio?
$9.9B across 87 disclosed U.S.-equity positions.
What is RTW INVESTMENTS, LP's 3-year performance?
+30% (13F-replication, price return), -42 pts vs the S&P 500. Not an audited fund return.
Where does this data come from?
U.S. SEC Form 13F-HR institutional holdings filings.
Sourced from SEC Form 13F-HR filings · Not investment advice ▾
Data as of 2026-03-31 · Methodology
13F-replication (price return, filing-date based) — not an audited fund return.
Published by WealthFile · Not investment advice.
Latest activity = change vs. the prior 13F. Avg buy price = est. entry over the trailing 3 years (gain = vs. latest price). Returns are 13F-replication, not audited fund returns. Sourced from SEC 13F filings.